Screener
Taysha Gene Therapies, Inc. TSHA Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344610
FAQ
- What is Taysha Gene Therapies, Inc.'s restricted cash?
- Taysha Gene Therapies, Inc. (TSHA) reported restricted cash of $0 in Q2 2026.
- How has Taysha Gene Therapies, Inc.'s restricted cash changed year-over-year?
- Taysha Gene Therapies, Inc.'s restricted cash decreased by 100.0% year-over-year, from $449K to $0.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s restricted cash?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s restricted cash has grown at a -35.8% compound annual growth rate (CAGR), from $2.64M to $449K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Taysha Gene Therapies, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude